{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:27:37Z","timestamp":1765974457790,"version":"build-2065373602"},"reference-count":7,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jaad.2022.05.042","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:50:22Z","timestamp":1653522622000},"page":"747-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Letter from the Editor: Cost-effectiveness of tuberculosis screening in patients already on biologic therapy"],"prefix":"10.1016","volume":"87","author":[{"given":"Dirk M.","family":"Elston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2022.05.042_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2020.09.006","article-title":"Hepatitis B reactivation in patients on biologics: a perfect storm","volume":"86","author":"Elston","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2022.05.042_bib2","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1473-3099(20)30276-0","article-title":"Interferon-\u03b3 release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis","volume":"20","author":"Zhou","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jaad.2022.05.042_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ccm.2019.07.007","article-title":"Diagnostic tests for latent tuberculosis infection","volume":"40","author":"Haas","year":"2019","journal-title":"Clin Chest Med"},{"issue":"4","key":"10.1016\/j.jaad.2022.05.042_bib4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40257-019-00432-y","article-title":"Active tuberculosis in patients with psoriasis receiving biologic therapy: a systematic review","volume":"20","author":"Snast","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2022.05.042_bib5","doi-asserted-by":"crossref","first-page":"e2278","DOI":"10.1093\/cid\/ciaa1135","article-title":"Optimal testing choice and diagnostic strategies for latent tuberculosis infection among US-born people living with human immunodeficiency virus (HIV)","volume":"73","author":"Pettit","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2022.05.042_bib6","article-title":"Performance of interferon-gamma release assays in the diagnosis of nontuberculous mycobacterial diseases-a retrospective survey from 2011 to 2019","volume":"10","author":"Yang","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"10.1016\/j.jaad.2022.05.042_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222008854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222008854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:04:57Z","timestamp":1759273497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222008854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0190962222008854"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.05.042","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter from the Editor: Cost-effectiveness of tuberculosis screening in patients already on biologic therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.05.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.05.027","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}